Friday 29 March 2019

Rivastigmine Market to Reflect Significant Incremental Opportunity By 2026


Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and Parkinson’s disease. The drug can be administered orally or in transdermal patches form, owing to its small molecular size.

Rivastigmine Market – Dynamics

Increasing geriatric population is a major driver for growth of the rivastigmine market. According to The Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular diseases worldwide also accounts for the development of Alzheimer’s disease, thereby boosting demand for rivastigmine. As per the National Center for Biotechnology Information published in 2013, the incidence of cardiovascular diseases was around 22.5 per 1,000 person worldwide which in turn suggesting a risk of dementia.Diseases such as diabetes and blood pressure can also increase the risk of dementia, which further boosts demand for rivastigmine, thereby propelling the market growth.


Rivastigmine Market – Regional Insights

The rivastigmine market is segregated geographically into North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the global rivastigmine market in 2017. This is owing to increasing prevalence of chronic kidney disease in the region that may lead to dementia. According to The American Kidney Fund, around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing to increasing geriatric population in the region. Geriatric population is more prone to dementia. According to World Population Prospects (WPP), in 2017, around 25% of the population in Europe was aged 60 years or above. According to the Alzheimer’s Association, in 2017, there was significant prevalence of vascular diseases in Latin America and Africa. Therefore, Latin America and Africa are expected to witness significant growth in the global rivastigmine market during the forecast period.

Rivastigmine Market – Competitive Landscape

Major players operating in the global rivastigmine market include, Novartis Europharm Limited, Actavis Pharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market are focused on product development and approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigmine tartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease.

Global Rivastigmine Market Taxonomy:

On the basis of disease indication, the global rivastigmine market is segmented into:

  • Alzheimer’s disease
  • Parkinson’s disease

On the basis of formulation, the global rivastigmine market is segmented into:

  • Capsules
  • Transdermal Patches


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Hyperspectral Imaging Market Scenario Highlighting Major Drivers & Trends Till 2026


Hyperspectral imaging (imaging spectroscopy) systems are the result of extensive research and activity efforts. These systems have various applications in sectors such as healthcare, research and development, food industry, defense sector and others such as remote sensing, calorimetry and night vision. Hyperspectral imaging differs from multispectral imaging based on quality of image and provides greater sensitivity than conventional or multispectral imaging. For instance, multispectral imaging provides 2 to 20 images per dataset, while hyperspectral imaging provides over 20 images per dataset. Also, multispectral imaging gives 4 to 20 data points per pixel, while hyperspectral imaging provides full spectrum per pixel.


Increasing deployment of hyperspectral imaging in healthcare sector creates a highly conducive environment for growth of the hyperspectral imaging market in the near future. Hyperspectral imaging finds wide application in medical imaging, ophthalmology, and is also used in the procedures of gastrointestinal tract, in vascular systems and in tissue diagnosis. It is also an integral part of wound analysis, cell biology, and fluorescence microscopy. Wide application of the technology is mainly attributed to its high accuracy and clarity.

Increasing adoption in pharmaceuticals sector fueling growth of the hyperspectral imaging market, especially in emerging economies

The global hyperspectral imaging systems market globe is expected to witness double digit growth in the near future. In healthcare sector, these systems are used to perform various procedures in the pharmaceuticals industry. These include systems used to perform quality control tests that help detect foreign material present in drugs, and also mixed chemicals in counterfeit drugs. Also, hyperspectral imaging systems help in identification of targeted tumor tissue, a blood vessel, lymph nodes, a nerve bundle by covering the surface area of target and providing the image, in which that pixels of the image contains information regarding various light wavelength bands. Also, hyperspectral imaging finds extensive application in cancer treatment, as these systems provide real-time data and help in understanding the changes of tissue, which occur in the early stages of development of disease, also it helps to differentiate healthy cells from cancerous cells.

Key Companies - Hyperspectral Imaging Market

Some are the key companies providing innovative products in this area are, Headwall Photonics, HyperMed Imaging, Inc, Spectral Imaging Ltd., imec, Norsk Elektro Optikk AS (NEO), SpekLED GmbH and Resonon.

Hyperspectral imaging market taxonomy:

Global Market by Product Type:
• Hyperspectral Imaging Cameras
• Other accessories

Global Market by Application:
• Diagnostic Imaging
• Biological (Wound Analysis, cell biology and fluorescence microscopy)
• Ophthalmology
• Pharmaceutical (Drug quality analysis)
• Surgery


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Antiepileptic Drugs Market Changing Dynamics Of Competition With Forecast To 2026


Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Epilepsy is categorized into generalized seizures and partial seizures based on the areas affected in the brain. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Seizures are further classified into mild seizures and stronger seizures depending on the severity of the seizures. The diagnosis of mild seizures are difficult, as its lasts only for few seconds. Stronger seizures may last for a few seconds to several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Epilepsy occurring due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.


Antiepileptic Drugs Market Drivers

Factors such as rising prevalence of epilepsy and robust pipeline are expected to boost the market growth over the forecast period. According to the study by Epilepsy Action Australia statistics in 2017, around 50 million people globally have epilepsy with around 80% of the people living in emerging economies such as India, Brazil, and China. Moreover, according to the Centers for Disease Control and Prevention, in 2017, an estimated 3.4 million people have active epilepsy in the U.S., which includes 3 million adults and 470,000 children. Manufacturers have potential drug molecules in the pipeline for the treatment of various forms of epilepsy. For instance, SK Life Sciences, Inc. has Cenobamate (YKP3089) in Phase 3 clinical trials. Eisai, Co., Ltd. has the drug Perampanel in Phase 2 clinical trials, and Marinus Pharmaceuticals, Inc. has the drug Ganaxolone in Phase II clinical trials. The expected launches of these drugs over the forecast period is expected to create favorable condition for the market growth.

Antiepileptic Drugs Market Regional Analysis

North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast period, owing to drug launches by leading manufacturers in the region. For instance, UCB Pharma received approval in Japan for Vimpat adjunctive therapy for partial onset seizures of epilepsy in 2016. Moreover, Eisai Pharma launched antiepilepsy drug Fycompa in India in 2017.

Antiepileptic Drugs Market Competitive Landscape

Key players operating in the global antiepileptic drugs market include GlaxoSmithKline plc, Johnson & Johnson, Valeant Pharmaceuticals International, Inc., Abbott Laboratories, Cephalon, Inc., Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Novartis AG, UCB Pharma Ltd., and Sanofi S.A.

Antiepileptic Drugs Market Taxonomy

The global antiepileptic drugs market is segmented on the basis of drug class, distribution channel, and region:

By Drug Class

  • First Generation
  • Second Generation
  • Third Generation


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Thursday 28 March 2019

Attention-deficit/Hyperactivity Disorder (ADHD) Treatment Market Trends Analysis Till 2026


Attention deficit hyperactivity disorder (ADHD) is a neural disorder. The disorder is characterized by impulsiveness, hyperactivity, and attention difficulty. Treatment of ADHD involves a combination of counseling, medications, and lifestyle changes. ADHD is the most commonly diagnosed mental disorder in adults and children with the exact cause being unidentified in the majority of cases. Researchers at the National Institute of Mental Health (NIMH) suggest the factors affecting mental illness include heredity, brain injuries, low birth weight, drugs use during pregnancy and exposure to environmental toxins such, as lead at young age. The currently available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments helps in reducing symptoms with improved functioning of patient.


Rising number of drug-treated patients for ADHD therapy is expected to drive the attention deficit hyperactivity disorder (ADHD) treatment market

According to the National Institute of Health estimates in 2015, the prevalence of ADHD is higher by 30% in boys, with 5.1 million children being diagnosed with ADHD globally in 2013 and the number expected to rise to 18 million by 2020. Increasing awareness of ADHD symptoms among patients and physicians, opinion-based diagnosis owing to the absence of standard diagnostic tests is expected to boost the revenue growth of ADHD therapeutics market in the forecast period. Additionally, rise in the ADHD therapeutics market is driven by increasing use of additives and preservatives in diet, value systems impacting quality of births, and changing lifestyles. However, restricted availability of non-stimulants ADHD drugs and existence of multiple conditions like schizophrenia or depression in children leads to underdiagnoses of ADHD in various geographies including Middle East and Africa, thereby restraining the growth of the market over the forecast period. Since Adderall abuse has grown to epidemic levels, our research team has compiled an article about the best all-natural alternatives to Adderall.

Drug development and market consolidation strategies fuel the demand of some manufacturers

Key players operating the attention deficit hyperactivity disorder (ADHD) treatment market include Eli Lilly, GlaxoSmithKline PLC, Pfizer Inc, Novartis AG and Shire PLC. The key strategies adopted by the manufacturers are developing cost-efficient drugs, which are safe for consumption and market consolidations. The other key vendors include Impax Laboratories, Hisamitsu Pharmaceutical Inc., Mallinckrodt Pharmaceuticals Inc., UCB S.A., Purdue Parma L.P and Johnson & Johnson.

The non-stimulants market segment accounts for highest revenue share owing to its efficient treatment improving focus and impulsivity

The global attention deficit hyperactivity disorder (ADHD) treatment market is segmented on the basis of drug type, distribution channel and geography.

On the basis of drug type, the global attention deficit hyperactivity disorder (ADHD) treatment market is segmented into:
• Stimulants
o Amphetamine
o Methylphenidate
o Dexmethylphenidate
o Dextroamphetamine
o Lisdexamfetamine Dimesylate
• Non-stimulants
o Atomoxetine
o Clonidine
o Guanfacine
o Bupropion

On the basis of therapy, the global attention deficit hyperactivity disorder (ADHD) treatment market is segmented into:
• Behavior Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: ,

Neurorehabilitation Devices Market Technological Advancements Insights to 2026


Neurorehabilitation is a well-elaborated therapist-supervised medical procedure, which aims at recovering a nervous system injury resulting from non-functional to functional nervous system and improving the well-being of a person. World health organization (WHO) survey of 2014, revealed that each year around 15 million people are affected by neurological disorders, from which around 5 million suffer from permanent disability. The report also revealed that, around 2.5 million people are affected with multiple sclerosis and 10 million with Parkinson’s disease, every year, throughout the world. Increase in the prevalence of neurological diseases among the populace, creates a huge need to introduce neurorehab centers and neurorehabilitation devices to ensure simplification of normal-routine life and decrease patients’ dependability on others.


Increase in opportunities and demand for neurorehabilitation devices in the market research industry

Higher incidences of neurological disorders has helped boost the demand for neurorehabilitation devices over the recent years. People’s awareness related to health and the increasing investment in healthcare industry have created a high demand for these devices. According to Centers for Disease Control and Prevention (CDCP) 2015, around 130,000 individuals face fatal strokes every year in the United States. Thus, the increasing need to reduce the incidences of strokes every year, has resulted in the increasing demand for neurorehabilitation devices. Large number of people who are affected by Parkinson’s disease are recorded in regions such as U.S., U.K., Finland, Iceland, and Ireland. These regions extensively employ neurorehabilitation devices, fueling market growth. Additionally, age plays a critical role in increasing the risk of neurological related disease. Thus, regions with higher geriatric populations lend immense opportunities for growth of the neurorehabilitation devices market. Neurorehabilitation devices such as wearable technology, nanotechnology, and robotics, primarily work towards improving the nervous system, in turn reducing disability and increasing ease of daily functioning of individuals.

Collaboration of key players to make lucrative developments

The major key players of neurorehabilitation devices market are Bioness, Inc., Ectron Ltd., Hocoma AG, Medtronic, Tyromotion, Agiliad, Bioxtreme Robotics Rehabilitation, St Jude Medical Inc., Alter G Inc., Denecor, Ekso Bionics Holding Inc., Helius, Interactive Motion Technologies, Kinestica, Kinetic Muscles, Medtronic Plc., and Neurostyle.

The neurorehabilitation devices market has been segmented on the basis of products, indication, and geography:

On the basis of products, the neurorehabilitation devices market is segmented into:

• Wearable Devices
• Brain computer Interface
• Neurorobotic System
• Non-invasive Stimulators

On the basis of indication, the neurorehabilitation devices market is segmented into:

• Parkinson’s Disease
• Stroke
• Traumatic Brain Injury
• Cerebral Palsy

On the basis of region, the neurorehabilitation devices market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Immunoprotein Diagnostic Testing Market Gaining a Strong Foothold 2026



Immunoproteins refers to blood proteins that are involved in playing a role in the functioning of the immune system. These proteins possess an immunological activity against pathogenic organisms and substances as they display an abnormal increase in blood concentration thereby acting as a potential indicator in disease diagnosis during an unhealthy state. The immunoproteins form an integrated body system in cells, tissues or organs that helps to neutralize the harmful effects of antigens. The immunoproteins also helps in the diagnosis of several diseases that includes infectious diseases, cardiovascular diseases and oncological conditions.

High prevalence rates of chronic diseases to push the sales of the global immunoprotein diagnostic testing market

The prime reason for growth in the demand for immunoprotein diagnostic testing services is the increase in prevalence and incidence rate of chronic diseases. According to WHO, the Global Health Observatory (GHO) data suggests that around 1.6 million which accounts up to 2.8% of the total deaths are caused due to diabetes. Moreover, the 2012, lung cancer alone was responsible to cause about 1.6 million deaths according to the statistics mentioned in the WHO report. To prevent such high mortality rates due to chronic disorders demands early diagnosis and suitable diagnostic testing. This is where the global immunoprotein diagnostic testing can serve a massive population thereby fueling its own growth at global level.

Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/502

Increase in geriatric population coupled with high prevalence of non- communicable diseases responsibe to propel the global immunoprotein diagnostic testing market

The major factors responsible to drive the global immunoprotein diagnostic testing market are the rise in geriatric population and the high prevalence and incidence rates of chronic diseases. According to WHO, the number of people suffering from Diabetes has risen from 108 million in 1980 to 422 million in 2014, suggesting rapid rise in the prevalence and incidence of diabetes. Moreover, according to Global Health Observatory data published by WHO in 2017, around 70% of global deaths accounting up to 39.5 million are caused due to non- communicable diseases (NCD) such as cardiovascular diseases, chronic lung diseases, cancers and diabetes.

Top Key Players :

The key players dominating the global immunoprotein diagnostic testing market includes Abbott Laboratories, Inc., Abcam PLC, Agilent Technologies, AdnaGen, BioMerieux, Enzo Life Sciences, Inc., Fujirebio Diagnostics, Inc., DiaSorin SPA, Roche, Randox Laboratories and Thermo Fisher Scientific. These companies are able to hold their position in the global immunoprotein diagnostic testing market due to consequent advancement in technological aspects. For instance, increasing sensitivity and ease of use while performing ELISA to develop radioimmunoassay keeping in mind the cost effective terms so as to make it accessible and affordable to a population that is price- sensitive.

The chemiluminescent segment exhibits a rapid growth in the global immunoprotein diagnostic testing that can be attributed to the wide scope of application and ease of use

The global immunoprotein diagnostic testing market is segmented on the basis of technology, test type, application and geographical regions.

On the basis of Technology,
• Radioimmunoassay
• Immunoturbidity Assay
• Chemiluminescence Assay
• Immunoprotein Electrophoresis
• Enzyme- based Immunoassay
• Immunofluorescence Assay

On the basis of Test Type,
• C- reactive Protein Diagnostic Test
• Complement System Protein Diagnostic Test
• Prealbumin Diagnostic Test
• Hepatoglobin Diagnostic Test
• Immunoglobulin Diagnostic Test
• Free Light Chain Diagnostic Test
• Others

Request For Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/502

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Wednesday 27 March 2019

Disposable Blood Bags Market Emerging Evolution and Opportunities Till 2026


Disposable blood bags are the biomedical devices used for collection, storage, transportation, and transfusion of blood and its components. In recent times, disposable plastic blood bags has replaced the usage of glass bottles due to problems associated with use of glass bottles including inadequate sterility, leading to blood contamination, and the presence of air bubbles resulted to severe complications during blood transfusion. Disposable plastic blood bags also help in the separation of blood components such as plasma, platelets, and cryoprecipitate, which are used to treat a range of blood disorders.

The global disposable blood bags market size was valued at US$ 230.1 million in 2017, and is expected to witness a CAGR of 12.1% over the forecast period (2018 – 2026).


Disposable Blood Bags Market - Competitive Landscape

Key players operating in the global disposable blood bags market include AdvacarePharma, Fresenius Kabi, Grifols, HLL Lifecare, Haemonetics Corporation, Macopharma, Neomedic, Poly Medicure, SURU International, Span Healthcare, and TERUMO PENPOL. Use of biosafety materials in the manufacturing of blood bags and favorable support from government authorities is expected to create huge growth opportunities for disposable blood bag manufacturers.

Increasing Prevalence of Blood Related Disorders such as Blood Cancer, Anemia, Sickle Cell Disease, Hemophilia, and Other Rare Blood Disorders is Expected to Drive the Disposable Blood Bags Market Revenue

Rising prevalence of diseases such as cancer and various blood related disorder (anemia, hemophilia, and sickle cell disease) is increasing demand for blood transfusion, which eventually drives growth of the disposable blood bags market. For instance, according to Red Cross Blood Organization facts of 2017 about blood needs, sickle cell disease affects 90,000 to 100,000 people in the U.S. and approximately 1,000 babies are born with the disease each year. Sickle cell patients often require blood transfusions throughout their lives.

Disposable Blood Bags Market - Regional Insights

On the basis of region, the global disposable blood bags market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2026, North America is expected to hold the leading position in the global disposable blood bags market, owing to well-established medical and healthcare infrastructure providing timely blood transfusion services. Growing awareness among people for blood donation is also a major factor driving growth of the disposable blood bags market. According to the Red Cross Blood Organization blood supply statistics of 2017, an estimated 6.8 million people in the U.S. donate blood every year.

Detailed Segmentation:

Global Disposable Blood Bags Market, By Blood Bag Type:

Collection Bags
- Single Collection Bags
- Double Collection Bags
- Triple Collection Bags
- Quadruple Collection Bags
Transfer Bags


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Intravenous Access Devices Market Demands and Gross Margin 2025


Intravenous access device are utilized by the physicians to deliver the medication to the patient’s blood stream through the intravenous route. Intravenous access device can also withdraw the blood for testing or diagnosis purpose. There are various therapies administrated by the intravenous access device which are included for the designation of specialty drugs. Intravenous access device prevent the air from entering the blood stream and allows the estimation of flow rate. Intravenous access devices are used for various purposes such as to correct the electrolyte imbalances, to deliver medications, fluid replacement or for blood transfusion whereas it can also be used when the patient is dehydrated.

Request For Customization of This Business Report @ https://www.coherentmarketinsights.com/insight/request-customization/567

Additionally intravenous access devices can be used for chemotherapy, chronic diseases such as diabetes, cancer, cardiovascular disorders, with acute infectious diseases also favors the growth of intravenous access devices market. Moreover, urbanization and growing geriatric population all over the world is expected to boost the growth of intravenous access device market.

Market Dynamics

Rising incidence of cardiovascular disease due to increase in the prevalence of diabetes, high blood pressure cases and number of smokers worldwide is expected to favor the demand for intravenous access device around the globe. According to World Health Organization (WHO), in 2015 around 17.7 million people died due to cardiovascular disease worldwide. Furthermore, the majority of deaths are occurred in emerging economies due to high prevalence rate and lack of healthcare services in rural areas. Also, increasing aging population and rising demand for intravenous access are the other factors leading to the growth of intravenous access device market in developed as well as emerging economies.

Rise in incidences of different disease is expected to fuel the growth of the intravenous access devices market in the near future.

North America accounts for the largest share in the global intravenous access devices market, followed by Europe. This mainly attributed to rapidly aging population, increase in the incidence rate of various disease such as cancer, kidney failure, diabetes and other life style inflicted diseases are some of the major factors that are expected to drive the intravenous access market. As per the stats published by Centers for Disease Control and Prevention (CDC), in 2012, around 29.1 people were living with diabetes in the U.S. Furthermore, in 2012, 1.7 million people were newly diagnosed for diabetes in U.S.

Intravenous Access Devices Market - Major Players

Some major players operating in the intravenous access devices market includes Becton, Dickinson and Company, B. Braun Melsungen AG, Teleflex, Inc., C.R. Bard, Inc., Fresenius Medical Care, Smiths Medical, Hospira, Inc., Covidien Plc, Fresenius Medical Care AG & Co., and Baxter International.

Detailed Segmentation:

Global Intravenous Access Devices Market, By Product Type:
• IV Catheters
• IV Infusion Pumps
• IV Needles

Global Intravenous Access Devices Market, By Catheters:
• Midline Peripheral Catheters
• Peripherally Inserted Central Catheters
• Centrally Inserted Central Catheters
• Others


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Tuesday 26 March 2019

Omeprazole Market size was valued at US$ 2,668.4 million in 2018


Omeprazole delayed-release capsules in combination with other medications are used to eliminate H. pylori, a bacteria causing ulcers and prevent the development of new ulcers in people with a history of ulcer formation of the small intestine. Prescription omeprazole is also used to treat higher acid producing stomach conditions such as Zollinger-Ellison syndrome in adults. According to the survey by Clinical Gastroenterology and Hepatology, 2012, ZES occurs in about one in every 1 million people, and is more common among men 30 to 50 years old.

Market Dynamics

Increasing prevalence of acid related diseases (ARDs) including gastroesophageal reflux disease (GERD) is a major factor driving omeprazole market growth. According to the research survey conducted by Florida Hospitals, 2015, pregnant women are at a higher risk of acid reflux, with an estimated 25% pregnant women experiencing the symptoms. The survey further stated that about 20% of people with acid reflux are at a higher risk of developing gastroesophageal reflux disease (GERD). Furthermore, increase in H.pylori infection and NSAID associated gastric and duodenal ulcers are expected to bolster market growth in the near future.


Also, launch of low-cost generic versions of omeprazole is expected to fuel market growth. For instance, in 2016, Dr. Reddy’s launched generic version to Zegerid capsules (omeprazole/sodium bicarbonate) for short-term treatment of stomach and duodenal ulcers, erosive esophagitis and heartburn associated with gastroesophageal reflux disease (GERD).

Increasing prevalence of peptic ulcers is expected to propel omeprazole market growth

Increasing prevalence of duodenal ulcers is expected to propel growth of the omeprazole market. According to a survey by Virtual Medical Center, 2016, peptic ulcer is the most common disease occurring in about 10-15% of the global population at a time. It is common in men and more common in elderly people. The survey further stated that duodenal ulcers are four times more common than gastric ulcers.

Increasing prevalence of H.pylori associated infection and favorable pricing policies to bolster the market growth

North America is expected to hold a dominant position in the global omeprazole market. This is owing to increasing number of people affected by H.pylori infection, which in turn is expected to increase the risk of gastric and duodenal ulcers. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Health Information Center, 2014, about 30 to 40 percent of people in the U.S. suffer from the H. pylori infection, thus increasing the risk of duodenal and gastric development.

Key Players

Major players operating in the global omeprazole market include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc, Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.

Detailed Segmentation:

Global Omeprazole Market, By Dosage Form:
  • Capsule
  • Powder
  • Tablet

Global Omeprazole Market, By Indication:
  • Duodenal Ulcer
  • Gastric Ulcer
  • Gastroesophageal Reflux Disease (GERD)
  • Erosive Esophagitis
  • Others


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Plasma Fractionation Market Size Will Escalate Rapidly in the Near Future


Plasma fractionation is a process of separating various components of plasma, which in turn is a component of blood obtained through blood fractionation. Plasma is separated and can be used for many different medical applications. Plasma is taken from donors when whole blood is donated, or by plasmapheresis - a process by which the liquid part of the blood, or plasma, is separated from the blood cells and plasma is retained. This plasma can be used as Fresh Frozen Plasma (FFP) for replacement of clotting factors. Most plasma is used for products which derived from plasma fractionation. Plasma comprehends thousands of diverse proteins, but only about 20 of these are used to produce therapeutic plasma products. These fit into three classes’ immunoglobulins, clotting factors, and albumin.


Growth of this market is mainly attributed to increasing incidence of bleeding and immune disorders, growing geriatric population, and growing use of immunoglobulin and alpha-1-antitrypsin. Plasma fractionation is used for treating protein deficiency in healthcare applications and also as a packaging material for industrial applications. The prime function of plasma fractionation is removal or inactivation of viruses and prions.

According to Centers of Disease Control (CDC) statistic, in 2012 chronic diseases were one of the major causes of death and disability in the U.S., with an estimated 117 million people suffering from some form of chronic disease. Developed diagnostic facilities, and comfort of access to healthcare along with increasing incidence and prevalence of chronic diseases all over the world, are some factors responsible for the rising demand for plasma derived products and is expected to drive the plasma fractionation market during the forecast period. The increase in geriatric population all over world is an important factor for plasma fractionation market, mainly due to the risk of complications of hemophilia, such as intracranial hemorrhage, inhibitor development, and joint diseases, increases along with the age of a person.

North America is leading the global plasma fractionation market, owing to growing per capita healthcare spending in the U.S. And also rising demands from patients for better and advanced healthcare facilities, and increased acceptance of new and advanced technologies. Asia Pacific region is also witnessing highest CAGR in the forecast period, due to factors such as increasing prevalence of hemophilia among developing countries such as China, and India, and increasing aging population in the Asia Pacific region.

Global Key Klayers - Plasma Fractionation Market

Key players operating in the global plasma fractionation market are CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A held the major share of the plasma fractionation market and will continue to take over the market. Other major players are Bio Products Laboratory, Sanquin, China Biologic Products, Inc., Biotest AG, and Laboratoire Français du Fractionnement et des Biotechnologies.


Plasma Fractionation Market

On the basis of product type, the global plasma fractionation market is classified into:
• Albumin
• Immunoglobulins
• Coagulation Factor Concentrates

On the basis of application, the global plasma fractionation market is classified into:
• Neurology
• Hematology
• Immunology
• Critical Care

On the basis of end user, the global plasma fractionation market is classified into:
• Hospitals
• Clinical Research Laboratories

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,

Smart Medical Devices Market Poised to Garner Maximum Revenues During 2018-2026


Smart medical devices refers to the electrical devices that have an autonomous processing system within them and are used to monitor a range of health and fitness parameters on an everyday basis. These devices provide a multitude of advantages to the patient and caregiver in monitoring and measuring various healthcare regimens such as sensing the lowered levels of insulin through artificial intelligence among type 1 diabetes patients and delivering insulin. Smart medical devices have radically changed the perspective of disease management by offering easy and sustainable solutions to patients at home and reducing the turn-around hospital visits. The integration of emerging technologies such as internet of things (IoT) in the smart medical devices have helped to build an interface between functionality and communication. These devices assists in simplifying the medical complexities and convert it into logical format that helps to obtain results in understandable form. Smart medical devices have the potential to enable the patients to deal with serious health disorders, which required the intervention of healthcare professionals in the earlier days.


Market Dynamics -

Increasing demand for better disease management tools and shift of populace towards smart medical devices are major factors propelling growth of global smart medical devices market. Chronic diseases such as diabetes, hypertension, asthma, and other chronic obstructive pulmonary disorders (COPD) are highly prevalent across the globe, which increases the demand for tools and services to manage their symptoms. For instance, according to the World Health Organization (WHO), in 2017, the number of people over 18 years of age suffering from diabetes have increased from 4.7% in 1980 to 8.5% of the global population by 2014. Moreover, the WHO also states that over 235 million people across the globe are suffering from asthma. The development of smart medical devices such as continuous glucose monitors as well as smart sensing wearable devices to monitor the patients suffering from various chronic diseases have resulted in the growth of smart medical devices market.

Regional Insights -

On the basis of region, the global smart medical devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global smart medical devices market and is expected to retain its dominance over the forecast period, owing to technological advancements and broadened recommendation of healthcare professionals for the use of these devices. For instance, Cycadia Health, a U.S. based start-up introduced a novel product named iTBra in 2017 with inbuilt sensors that helps to keep track of patient’s breast health by monitoring the rhythmic pattern and conditions of the breast tissues.

Competitive Insights -

The key players operating in the global smart medical devices market include Apple, Inc., Fitbit, Inc., F. Hoffmann-La-Roche, Abbott Laboratories, Medtronic Plc, Dexcom, Inc., NeuroMatrix, Inc., Johnson & Johnson, and others. Market players are focused towards providing technologically advanced products to sustain their presence in the market. For instance, in April 2018, Teradata introduced the first 4D analytics that can be used in wearable and personal medical devices to translate the three dimensional geospatial location data with time as the fourth dimension.

Market Taxonomy -

On the basis of device type, the global smart medical devices market is segmented into:

Diagnostics and Monitoring Devices:
  • Blood Glucose Monitors
  • Heart Rate Monitors
  • Pulse Oximeters
  • Breath Analyzers
  • Medical Tricoders
  • Smart Clothing
  • Smart Watches
  • Others
  • Therapeutic Devices
  • Insulin Pumps

Portable Oxygen Concentrators & ventilators:
  • Hearing Aids
  • Others


About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702

CMI Research Reports at No comments:
Labels: , ,
Subscribe to: Posts (Atom)